GlassScriptPhysician profile
Georgette Hattier
NPI 1497377303
$5,254.72
in general payments reported to CMS, 2019-2025
25 companies · $3,071 in 2025
The $3,071 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.29 · 2022: $619 · 2023: $245 · 2024: $1,277 · 2025: $3,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,348 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,348.46 |
| Education | $244.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,541.38 | 2022-2025 | |
| Janssen Biotech, INC. | $576.51 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $573.26 | 2025 | Nemluvio |
| Genzyme Corporation | $526.16 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $491.21 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $397.68 | 2022-2025 | Dupixent |
| Ucb, INC. | $282.11 | 2024-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $269.17 | 2022-2025 | Sotyktu |
| Journey Medical Corporation | $119.73 | 2025 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Vapotherm INC | $43.47 | 2021-2022 | |
| Almirall LLC | $34.74 | 2025 | Seysara |
| Convatec INC. | $32.68 | 2024 | |
| Arcutis Biotherapeutics, INC. | $30.76 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $27.92 | 2024 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $27.13 | 2025 | Novachor |
| Sun Pharmaceutical Industries INC. | $26.18 | 2024 | |
| Lnhc, INC | $26.14 | 2025 | Zelsuvmi |
| Organon LLC | $25.66 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.82 | 2025 | Jublia |
| Helsinn Therapeutics (U.S.), INC. | $23.11 | 2023 | Valchlor |
| Janssen Scientific Affairs, LLC | $22.09 | 2025 | Tremfya |
| Incyte Corporation | $22.04 | 2024 | Opzelura |
| Pfizer INC. | $15.44 | 2025 | |
| Lilly USA, LLC | $15.34 | 2025 | Taltz, Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgette Hattier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.